MedTrace Logo

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

NCT00994123 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2016-08-22

Study results available
· View outcomes & findings →

Summary

A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

MM-121

MM-121 (SAR256212) = intravenous solution

DRUG

Erlotinib

erlotinib = daily oral tablet

Sponsors & Collaborators

  • Merrimack Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Victor Moyo, MD · Merrimack Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2014-11-30
Completion
2015-06-30

Countries

  • United States
  • Canada
  • Germany
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00994123 on ClinicalTrials.gov